Skip to main content

BeNeLuxA

Hauptnavigation

  • News
    • Beneluxa reaching out to other collaborations
    • Joint HTA assessment on autologous gene therapy Libmeldy
    • Pharmaceutical Developments on Haemophilia
    • Archive
  • About
    • Beneluxa initiative
    • Mandate and organisation
    • Benefits
  • Statements
  • Activities
    • Horizon Scanning
    • Health Technology Assessment
      • HTA procedures within the Beneluxa Initiative
    • Information Sharing
      • Patient registries
    • Pricing and reimbursement
  • Documents
    • Background documents
    • Publications
    • Press releases
    • Templates
  • Contact
  • xclose
Contact
contact us
Activities
Symbolic chart
Beneluxa initiative
map

The Beneluxa Initiative aims to ensure sustainable access
to innovative medicine at affordable cost for our patients.

Beneluxa reaching out to other collaborations: international experience sharing on negotiations of new pharmaceuticals

From the 27th – 28th of June 2022, Amgros and the Nordic Pharmaceutical Forum hosted an international workshop on negotiations on new pharmaceuticals with representatives from organizations in 9…
more: Beneluxa reaching out to other collaborations: international experience sharing on negotiations of new pharmaceuticals

Ireland, Belgium and the Netherlands complete joint HTA report on gene therapy Libmeldy

The first step in the joint reimbursement process for Libmeldy® (atidarsagene autotemcel), a gene therapy product for the treatment of children with metachromatic leukodystrophy, was successfully…
more: Ireland, Belgium and the Netherlands complete joint HTA report on gene therapy Libmeldy

Pharmaceutical Developments on Haemophilia

This report, written by the Taskforce Horizon Scanning of the Beneluxa Initiative, describes the current situation of Haemophilia and provides an overview of new pharmaceutical developments regarding…
more: Pharmaceutical Developments on Haemophilia

Contact

info@beneluxa.org

Info

Disclaimer

Links

About

Back to top